Novo Nordisk's Catalent Approval Improves Supply Visibility -- Market Talk
1346 GMT - The receipt of all regulatory approvals allowing Novo Nordisk's Catalent acquisition is important and should see share price upside as it improves supply visibility, Bank of America Securities analysts Sachin Jain and Graham Parry write. The acquisition is expected to gradually increase Novo's filling capacity from 2026 onwards. However, share price upside potential may be capped given investor nerves into the imminent phase 3 trial data from obesity drug CagriSema, they say. The bank expects around 10% share price upside potential if CagriSema confirms 25% weight loss, versus 15%-20% share price upside potential if weight-loss is over 27%. Shares rise 1.8% to 767.50 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 08:46 ET (13:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available